XTuit Pharmaceuticals, Inc. is developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. Their proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s founders include Rakesh K. Jain, Ph.D. (Harvard Medical School and Massachusetts General Hospital), Robert Langer, Sc.D. (MIT), Ronald Evans, Ph.D. (Salk Institute), and Alan Crane (Polaris Partners). In addition to CTI Life Sciences Fund II, XTuit is backed by leading investors including Polaris Partners, New Enterprise Associates, Arcus Ventures and Omega Funds.
Telephone: (781) 290-0770